WEE1
37 programs · 37 companies
Programs
37
Companies
37
Active Trials
20
Targeting WEE1
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| TAK-2403 | Takeda | Phase 2 | FSGSWilms | |
| Sovacapivasertib | Amgen | Phase 3 | CFSchizophrenia | |
| Fixaglumide | Genmab | Phase 2/3 | ThymomaCervical Ca | |
| Sovarasimod | Halozyme | Phase 1/2 | CeliacCKD | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | Cervical CaNSCLC | |
| Talazumab | Zealand Pharma | Phase 1/2 | ASPancreatic Ca | |
| PEK-IIT-463 | Peking Univ Cancer Hosp | Preclinical | ADPKD | |
| Kemalemzoparlimab | Precision Bio | Phase 2 | Pompe | |
| INO-2656 | Inovio | Approved | LGSSCD | |
| CAD-8013 | Candel Therapeutics | Phase 3 | Ovarian CaCF | |
| CAL-4725 | Calithera Bio | Preclinical | Hemophilia ADravet | |
| MIN-7010 | MiNT Therapeutics | Phase 1 | Pancreatic Ca | |
| Suramavacamten | Imago (Merck) | Phase 3 | IPFSCLC | |
| Ceviosocimab | Alto Neuroscience | Preclinical | PBCWM | |
| Sovafutibatinib | Taro Pharma | NDA/BLA | LN | |
| COR-2320 | Corvus (Angel) | Preclinical | CTCLOCD | |
| ABB-879 | Abbisko | Phase 1 | MigraineALS | |
| 109-1876 | CSPC Pharma | Preclinical | DravetSLE | |
| Talatinib | Nvelop Ther | Approved | Gastric CaMCC | |
| MIR-6154 | MedMira | Phase 2 | NSCLCCeliac | |
| Nirazumab | 4D Molecular | Phase 2/3 | HCCPBC | |
| TVT-9611 | Travere Ther | NDA/BLA | Narcolepsy | |
| Gozederotide | Frontier Med | NDA/BLA | LGSNarcolepsy | |
| Niraglumide | Nichi-Iko | Phase 2 | GA | |
| GLA-2545 | Gland Pharma | Phase 2 | FLSLE | |
| Kemarelsin | Harbour BioMed | NDA/BLA | ALS | |
| Tixatinib | BTG (Boston Sci) | Phase 2 | Parkinson's | |
| MOL-8666 | Molecular Partners | Approved | PVRB | |
| MAG-3823 | MagForce | Phase 1 | MSRA | |
| Bemacilimab | Celyad Oncology | NDA/BLA | RettT2D | |
| ESC-346 | Esco Lifesciences | Phase 1 | UCAML | |
| THA-9190 | Thai Otsuka | Preclinical | CMLOCD | |
| CHA-IIT-602 | Charité Berlin | NDA/BLA | RA | |
| RUI-IIT-202 | Ruijin Hospital | Phase 1 | OCD | |
| AII-IIT-938 | AIIMS New Delhi | Preclinical | Dravet | |
| Polalemzoparlimab | Grand Pharma | Phase 1 | NASHPompe | |
| 600-5970 | Humanwell Healthcare | Approved | Crohn's |